Tesamorelin for Belly Fat: Research & Results

Visceral fat surrounding internal organs is linked to cardiovascular disease, diabetes, and metabolic syndrome. It is notoriously resistant to diet and exercise alone.

Tesamorelin stimulates natural GH release from the pituitary, and GH preferentially mobilizes visceral fat. Unlike synthetic GH, it maintains the body's natural pulsatile release pattern.

• GHRH Stimulation: Triggers natural growth hormone release
• IGF-1 Elevation: Drives fat metabolism
• Visceral Fat Targeting: GH preferentially mobilizes visceral adipose
• Lipolysis: Activates hormone-sensitive lipase in visceral fat cells
• Preserved Muscle: Helps maintain lean mass during fat loss

Tesamorelin has robust clinical data:

• Phase III (Falutz et al., 2007): 412 patients showed average 18% VAT reduction over 26 weeks vs placebo.
• Extension Study: 52 weeks maintained reduction and improved lipid profiles.
• Non-HIV: Smaller studies show similar trends in non-HIV populations.

Evidence level: Strong — Phase III data and FDA approval. Among the strongest evidence for any peptide's fat-loss effects.

• Dosage: 2 mg per day subcutaneously
• Timing: Once daily in the abdomen
• Duration: 26–52 weeks in clinical trials

Some protocols reference lower doses (1 mg/day) for general wellness.

• Week 2–4: Improved sleep and energy from optimized GH
• Week 4–8: Measurable waist circumference reduction
• Week 8–12: Visible belly fat reduction
• Week 12–26: ~18% VAT reduction per clinical data

Ascension Peptides provides research-grade tesamorelin:

• ≥98% HPLC-verified purity
• Third-party COA documentation
• Proper lyophilized format

Tesamorelin is also available by prescription as Egrifta®.